Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial –

– Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate –

Read more at globenewswire.com